AA
AAPG.US Ascentage Pharma Group International
- Market cap
- USD 1.40B
- P/E
- -
- P/B
- 16.80x
- ROE
- -520.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is AAPG.US undervalued?
Graham numberThe Graham number of Ascentage Pharma Group International cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ascentage Pharma Group International fundamental analysis
No fundamental analysis for Ascentage Pharma Group International yet.
Ascentage Pharma Group International stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ascentage Pharma Group International
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecul…
Full company profileAscentage Pharma Group International financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ascentage Pharma Group International annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 7.67M | 6.33M | 6.81M | 14.5M | 12.5M | 27.9M | 210M | 222M | 981M | 558M | 1.27B |
| Gross Profit | 7.41M | 6.33M | 6.81M | 12.4M | 10.5M | 24.6M | 188M | 191M | 952M | 427M | 1.03B |
| Operating Income | -115M | -131M | -345M | -583M | -664M | -870M | -850M | -873M | -370M | -1.18B | -2.77B |
| EBITDA | -116M | -49.7M | -327M | -1.47B | -641M | -787M | -771M | -744M | -238M | -1.09B | -2.60B |
| Net Income | -108M | -119M | -345M | -1.48B | -678M | -782M | -883M | -926M | -405M | -1.21B | -2.90B |
| EPS | -8.33 | -9.16 | -27 | -112 | -50 | -49 | -54 | -52 | -5.37 | -14 | -31 |
| Balance Sheet | |||||||||||
| Total Assets | 593M | 582M | 1.23B | 1.21B | 1.73B | 2.94B | 2.83B | 2.50B | 2.62B | 3.97B | 3.24B |
| Total Liabilities | 608M | 713M | 2.24B | 315M | 884M | 1.71B | 2.42B | 2.43B | 2.34B | 2.63B | 2.68B |
| Shareholders' Equity | -14.6M | -132M | -1.01B | 890M | 847M | 1.23B | 409M | 60.4M | 264M | 1.33B | 557M |
| Cash & Short-term Investments | 452M | 399M | 971M | 879M | 1.02B | 1.71B | 1.48B | 1.07B | 1.24B | 2.47B | 1.90B |
| Total Debt | 830K | 4.90M | 42.0M | 101M | 530M | 1.08B | 1.79B | 1.80B | 1.67B | 1.98B | 2.10B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -45.9M | -108M | -238M | -460M | -610M | -605M | -654M | -726M | -111M | -1.17B | -2.76B |
| Capital Expenditure | 3.37M | 20.5M | 49.5M | 81.4M | 251M | 437M | 237M | 56.8M | 24.3M | 27.6M | 39.0M |
| Free Cash Flow | -49.3M | -129M | -287M | -542M | -861M | -1.04B | -891M | -783M | -136M | -1.20B | -2.80B |
| Ratios | |||||||||||
| ROE | - | - | - | -166.3% | -80.0% | -63.4% | -216.1% | -1,532.1% | -153.5% | -91.2% | -520.2% |
| ROA | -18.2% | -20.4% | -28.1% | -122.9% | -39.1% | -26.6% | -31.2% | -37.0% | -15.5% | -30.5% | -89.3% |
| Net Profit Margin | -1,406.5% | -1,872.9% | -5,072.8% | -10,202.7% | -5,442.6% | -2,803.4% | -421.0% | -417.0% | -41.3% | -216.5% | -228.7% |
| Debt to Equity | - | - | - | 0.11x | 0.63x | 0.88x | 4.39x | 29.72x | 6.32x | 1.49x | 3.76x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ascentage Pharma Group International dividends
Ascentage Pharma Group International has not paid dividends in the last 9 fiscal years.
Who owns Ascentage Pharma Group International
- Insiders 0.00%
- Institutions 0.04%
- Public & others 99.96%
- Shares outstanding 93.4M
- Free float 71.5M
Top funds holding AAPG.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 1.56K | 0.00% | 0.00% | Aug 2026 |
Top institutions holding AAPG.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Point72 Asset Management, L.P. | 13.8K | 0.01% | -13.80% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 919.00 | 0.00% | +84.54% | Jun 2026 |
| Wells Fargo & Co | 200.00 | 0.00% | 0.00% | Jun 2026 |
| EverSource Wealth Advisors, LLC | 24.00 | 0.00% | 0.00% | Jun 2026 |
| UBS Group AG | 15.00 | 0.00% | -87.90% | Jun 2026 |
| BlackRock Inc | 6.00 | 0.00% | 0.00% | Jun 2026 |
| Royal Bank of Canada | 6.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 1.00 | 0.00% | 0.00% | Jun 2026 |
| XY Capital Ltd | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Tower Research Capital LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Ascentage Pharma Group International company profile
- Company name
- Ascentage Pharma Group International
- Ticker
- AAPG.US
- Exchange
- USA Stocks
- Listed since
- Jan 24, 2025
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 828
- Fiscal year end
- December
- Address
- Suzhou Industrial Park, Suzhou, China, 215000
- Phone
- 86 512 8555 7777
- Website
- ascentage.cn
About Ascentage Pharma Group International
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has strategic partnership with biotechnology and pharmaceutical companies; research institutions; and Peking University to build a collaborative system for hematological oncology. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Ascentage Pharma Group International management
10- Dr. Dajun Yang M.D., Ph.D.Co-Founder, Chairman & CEO · born 1963
- Dr. Shaomeng Wang Ph.D.Co-Founder, Chief Scientific Advisor & Non-Executive Director · born 1965
- Dr. Ming Guo Ph.D.Co-Founder · born 1958
- Dr. Veet MisraChief Financial Officer
- Yuly ChenSenior Director of Investor Relations
- Mr. Thomas Joseph Knapp J.D.Senior VP & General Counsel · born 1953
- Dr. Yifan Zhai M.D., Ph.D.Chief Medical Officer · born 1963
- Dr. Chongdong FuSenior VP & Head of CMC
- Mr. Jin CaoHead of Finance · born 1986
- Mr. James Ziegler M.B.A.Chief Commercial Officer · born 1966